

Instructions for Authors 2015

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "review", "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Acknowledgements*; (h) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures should appear inline in the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are subject to color charges.

Tables. All tables should appear inline in the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

References. Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

Nomenclature and Abbreviations. Nomenclature should follow that given in "Chemical Abstracts", "Index Medicus", "Merck Index", "IUPAC –IUB", "Bergey's Manual of Determinative Bacteriology", The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions for Authors regarding the format of your manuscript and references.

Manuscripts must be submitted only through our online submission system at: <http://www.iiar-submissions.com/login.html>

In case a submission is incomplete, the corresponding Author will be notified accordingly.

Questions regarding difficulties in using the online submission system should be addressed to: email: journals@iiar-anticancer.org

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles published in 2015 are entitled to a complimentary online subscription to Anticancer Research 2015. Requests should be addressed to the Editorial Office. Galley proofs should be returned corrected to the Editorial Office by email within two days.

Copyright© 2015 - International Institute of Anticancer Research (J.G. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

Specific information and additional instructions for Authors

1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of immediate importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress.
2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees. (For further information please click here)
3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission.

4. Each manuscript submitted to AR is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR, are treated in confidence, without access to any person other than the Managing Editor, the journal's secretary, the reviewers and the printers.
5. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author's writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.
6. Authors should pay attention to the following points when writing an article for AR:
 - The Instructions to Authors must be followed in every detail.
 - The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
 - The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
 - Results given in figures should not be repeated in tables.
 - Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
 - Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
 - Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
 - Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
 - Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
 - The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
 - By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.
7. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.
8. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).
9. Articles submitted to AR may be rejected without review if:
 - they do not fall within the journal's policy.
 - they do not follow the instructions to authors.
 - language is unclear.
 - results are not sufficient to support a final conclusion.
 - results are not objectively based on valid experiments.
 - they repeat results already published by the same or other authors before the submission to AR.
 - plagiarism is detected by plagiarism screening services.

(Rejection rate (2014): 65%).
10. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.
11. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iiar-anticancer.org
12. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.
13. Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service.

(This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of AR).

CANCER GENOMICS & PROTEOMICS

www.cgp.iarjournals.org

Print ISSN (2004-2012): 1109-6535

Online ISSN: 1790-6245

VOL. 1 (2004) - VOL. 9 (2012) (print and online)
From VOL. 10 (2013) online – only and open access



International Online **Open Access** Journal

General Policy. CANCER GENOMICS & PROTEOMICS (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

CGP will also accept abstracts and proceedings of scientific meetings for publication, following consideration and approval by the Editorial Board.

A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 1-3 months from submission or 1-2 months from acceptance.

CGP is published bimonthly by the **International Institute of Anticancer Research** and is available online with **Stanford University HighWire Press**. For more information please visit our website www.cgp.iarjournals.org.

Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389. E-mail: journals@iiar-anticancer.org; IIAR websites: www.iiar-anticancer.org and www.iarjournals.org

A Selection of Recent Articles

The Metastasis Suppressor NME1 Regulates Expression of Genes Linked to Metastasis and Patient Outcome in Melanoma and Breast Carcinoma. J.R. MCCORKLE, M.K. LEONARD, S.D. KRANER, E.M. BLALOCK, D. MA, S.G. ZIMMER, D.M. KAETZEL (*Memphis, TN; Baltimore, MD; Lexington, KY; Iowa City, IA, USA*)

Profiling of Chromosomal Changes in Potentially Malignant and Malignant Oral Mucosal Lesions from South and South-East Asia Using Array-Comparative Genomic Hybridization. M.L.S. LUNDE, E. ROMAN, S. WARNAKULASURIYA, R. MEHROTRA, J. LARANNE, E.N. VASSTRAND, S.O. IBRAHIM (*Bergen, Norway; London, UK; Allahabad, India; Tampere, Finland*)

Expression of Claudins in Human Clear Cell Renal Cell Carcinoma. W. MEN, T.A. MARTIN, F. RUGE, N. ZHANG, P. DU, Y. YANG, W.G. JIANG (*Beijing, China; Cardiff, UK*)

TCR-MHC/Peptide Interaction: Prospects for New Anti-tumoral Agents. U.H. WEIDLE, G. GEORGES, G. TIEFENTHALER (*Penzberg, Germany*)

Modulation of Liver-Intestine Cadherin (Cadherin 17) Expression, ERK Phosphorylation and WNT Signaling in EPHB6 Receptor-expressing MDA-MB-231 Cells. L. BHUSHAN, N. TAVITIAN, D. DEY, Z. TUMUR, C. PARSA, R.P. KANDPAL (*Pomona, CA, USA*)

Phenome-Genome Association Studies of Pancreatic Cancer: New Targets for Therapy and Diagnosis. R. NARAYANAN (*Boca Raton, FL, USA*)

Usefulness of Nanofluidic Digital PCR Arrays to Quantify T790M Mutation in EGFR-mutant Lung Adenocarcinoma. K. ISOBE, Y. HATA, N. TOCHIGI, K. KABURAKI, H. KOBAYASHI, T. MAKINO, H. OTSUKA, F. ISHIDA, N. HIROTA, G. SANO, K. SUGINO, S. SAKAMOTO, Y. TAKAI, K. SHIBUYA, A. IYODA, S. HOMMA (*Tokyo, Japan*)

Quantitative Proteomics of Bronchoalveolar Lavage Fluid in Lung Adenocarcinoma. S.A. ALMATROODI, C.F. MCDONALD, A.L. COLLINS, I.A. DARBY, D.S. POUNIOTIS (*Bundoora; Heidelberg, VIC, Australia; Buraidah, Saudi Arabia*)

Metabolic profile of Triple-negative Breast Cancer in African-American Women Reveals Potential Biomarkers of Aggressive Disease. Y.M. KANAAN, B.P. SAMPEY, D. BEYENE, A.K. ESNAKULA, T.J. NAAB, L.J. RICKS-SANTI, S. DASI, A. DAY, K.W. BLACKMAN, W. FREDERICK, R.L. COPELAND, E. GABRIELSON, R.L. DEWITTY JR. (*Washington DC; Durham, NC; Cleveland, OH; Hampton, VA; Baltimore, MD, USA*)

Analysis of SHOX2 Methylation as an Aid to Cytology in Lung Cancer Diagnosis. P. ILSE, S. BIESTERFELD, N. POMJANSKI, C. WROBEL, M. SCHRAMM (*Düsseldorf, Germany*)

The Role of Apurinic/Apyrimidinic Endonuclease DNA Repair Gene in Endometriosis. C.-M. HSU, W.-S. CHANG, J.-J. HWANG, J.-Y. WANG, Y.-L. HSIAO, C.-W. TSAI, J.-C. LIU, T.-H. YING, D.-T. BAU (*Taichung; Taipei, Taiwan, ROC*)

Epigenetic Silencing of GNMT Gene in Pancreatic Adenocarcinoma. A. BOTEZATU, C. BLEOTU, A. NASTASE, G. ANTON, N. BACALBASA, D. DUDA, S.O. DIMA, I. POPESCU (*Bucharest, Romania; Charlestown, MA, USA*)

PDK1 is Expressed in Ovarian Serous Carcinoma and Correlates with Improved Survival in High-grade Tumors. P. LOHNEIS, S. DARB-ESFAHANI, M. DIETEL, I. BRAICU, J. SEHOULI, R. ARSENIC (<i>Berlin, Germany</i>)	6329
Clinical Significance of Multinodularity in Patients with Papillary Thyroid Carcinoma. D. KUST, N. MATEŠA, Z. KUSIĆ (<i>Zagreb, Croatia</i>).....	6335
Biparametric Magnetic Resonance Imaging as an Adjunct to CA125 and HE4 to Improve Characterization of Large Ovarian Masses. L. MANGANARO, E. ANASTASI, M.G. PORPORA, V. VINCI, M. SALDARI, S. BERNARDO, L. BALLELIO, P. SOLLAZZO, I. PECORELLA, N. RECCHIA, F. STRACCI, P.B. PANICI, A. ANGELONI, C. CATALANO, M. SCIALPI (<i>Rome; Perugia, Italy</i>)	6341
Errata	6353
Retraction	6354

Induction Chemotherapy and Sequential Concomitant Chemo-radiation in Locally Advanced Head and Neck Cancers: How Induction-phase Intensity and Treatment Breaks May Impact on Clinical Outcomes. P. FRANCO, I. POTENZA, M. SCHENA, G. RIVA, G. PECORARI, P. GARZINO DEMO, M. FASOLIS, F. MORETTO, M. GARZARO, J. DI MUZIO, M. MELANO, M. AIROLDI, R. RAGONA, M. RAMPINO, U. RICARDI (<i>Turin, Italy</i>)	6247
Platinum–Vinorelbine Induction Chemotherapy plus Bevacizumab With and Without Pemetrexed Switch Maintenance in Advanced NSCLC. L. MICHELSEN, J.B. SØRENSEN (<i>Copenhagen, Denmark</i>).....	6255
Second-line Chemotherapy for Patients with Small Cell Lung Cancer and Interstitial Lung Disease. D. FUJIMOTO, R. SHIMIZU, R. KATO, Y. SATO, M. KOGO, J. ITO, S. TERAOKA, T. OTOSHI, K. NAGATA, A. NAKAGAWA, K. OTSUKA, N. KATAKAMI, K. TOMII (<i>Kobe, Japan</i>)	6261
MR Spectroscopic Profile of an Angiocentric Glioma. M.T. WHITEHEAD, G. VEZINA (<i>Washington, DC, USA</i>).....	6267
Development and Validation of a Novel Plasma Protein Signature for Breast Cancer Diagnosis by Using Multiple Reaction Monitoring-based Mass Spectrometry. H.-B. LEE, U.-B. KANG, H.-G. MOON, J. LEE, K.-M. LEE, M. YI, Y.S. PARK, J.W. LEE, J.-H. YU, S.H. CHOI, S.H. CHO, C. LEE, W. HAN, D.-Y. NOH (<i>Seoul; Gyeonggi-do, Republic of Korea</i>)	6271
Prevalence of Vitamin D Deficiency in Patients with Bone Metastases and Multiple Myeloma. G.S. MAIER, K. HORAS, A.A. KURTH, D. LAZOVIC, J.B. SEEGER, U. MAUS (<i>Oldenburg; Ratingen; Giessen, Germany; Sydney, NSW, Australia</i>).....	6281
Induction of Acute Myeloid Leukemia with Idarubicin, Cytarabine and Cladribine. E. WIEDOWER, O. JAMY, M.G. MARTIN (<i>Memphis, TN, USA</i>).....	6287
Expression of p16/Ki-67 in ASC-US/LSIL or Normal Cytology with Presence of Oncogenic HPV DNA. C. SOLARES, J. VELASCO, E. ÁLVAREZ-RUIZ, L. GONZÁLEZ-FERNÁNDEZ, A. ENCINAS, A. ASTUDILLO, J. SCHNEIDER (<i>Avilés; Oviedo; Madrid, Spain</i>)	6291
Contribution of <i>Interleukin-4</i> Genotypes to Lung Cancer Risk in Taiwan. W.-S. CHANG, S.-C. WANG, C.-L. CHUANG, H.-X. JI, C.-L. HSIAO, C.-M. HSU, C.-W. TSAI, S.-P. LIU, P.-C. HSU, Y.-L. LO, D.-T. BAU (<i>Taichung; Taoyuan; Taipei, Taiwan, ROC</i>)	6297
Long-term Survival with Ipilimumab: Experience from a National Expanded Access Program for Patients with Melanoma. I. KRAJSOVÁ, P. ARENBERGER, R. LAKOMÝ, E. KUBALA, I. BŘEZINOVÁ, A. POPRACH, M. ŠŤASTNÝ, J. MUŽÍK, B. MELICHAR (<i>Prague; Brno; Hradec Králové; Ostrava; Olomouc, Czech Republic</i>)	6303
Dietetic and Psychological Mindfulness Workshops for the Management of Cachectic Cancer Patients. A Randomized Study. C. FOCAN, G. HOUBIERS, L. GILLES, T. VAN STEELAND, N. GEORGES, A. MANIGLIA, J.-P. LOBELLE, V. BARO, M.-P. GRAAS (<i>Liège, Belgium</i>)	6311
Ureteral Metastasis: Uncommon Manifestation in Prostate Cancer. D. SCHALLIER, B. RAPPE, M. CARPRIAUX, F. VANDENBROUCKE (<i>Brussels; Aalst, Belgium</i>).....	6317
Surgical Management of Duodenal Gastrointestinal Stromal Tumors: A Case Report. K. MRAK, B. LIEGL-ATZWANGER, J. HAYBAECK, W. PETRITSCH, H.-J. MISCHINGER, P. KORNPAT (<i>Graz, Austria</i>)	6321
Unresectable Middle Mediastinal Biphasic Pulmonary Blastoma. K. GALLO, A. BRICKMAN, W.H. WARREN, P. GATTUSO, C.W. SEDER (<i>Chicago, IL, USA</i>)	6325

Tumor-like Chronic Pancreatitis Is Often Autoimmune Pancreatitis. S. RÄTY, J. SAND, I. NORDBACK, I. RINTA-KIIKKA, K. VASAMA, J. HAGSTRÖM, S. NORDLING, J. SIRÉN, T. KIVILUOTO, C. HAGLUND (<i>Tampere; Helsinki, Finland</i>)	6163
Translocation (1;5) in a Glomus Tumor. J. NISHIO, K. NABESHIMA, S. MORI, M. NAITO (<i>Fukuoka, Japan</i>)	6167
Extraskelatal Myxoid Chondrosarcoma Presenting as a Plantar Fibroma: Case Report and Review of the Literature. M.G. LOCKYER, D.G. ROSEN (<i>Houston, TX, USA</i>)	6171
Prophylactic Effect of Oral Minocycline in Combination with Topical Steroid and Skin Care Against Panitumumab-induced Acneiform Rash in Metastatic Colorectal Cancer Patients. M. YAMADA, H. IHARA, H. FUJII, M. ISHIHARA, N. MATSUHASHI, T. TAKAHASHI, K. YOSHIDA, Y. ITOH (<i>Gifu, Japan</i>) ...	6175
Risk Factors for Recurrence After Curative Conversion Surgery for Unresectable Gastric Cancer. M. FUKUCHI, T. ISHIGURO, K. OGATA, A. KIMURA, Y. KUMAGAI, K. ISHIBASHI, H. ISHIDA, H. KUWANO, E. MOCHIKI (<i>Kawagoe; Maebashi, Japan</i>)	6183
Metastatic Spinal Cord Compression: A Survival Score Particularly Developed for Elderly Prostate Cancer Patients. D. RADES, A.J. CONDE-MORENO, J. CACICEDO, B. SEGEDIN, T. VENINGA, S.E. SCHILD (<i>Lübeck, Germany; Castellón; Vizcaya, Spain; Ljubljana, Slovenia; Tilburg, the Netherlands; Scottsdale, AZ, USA</i>)	6189
Fluctuation in Plasma 5-Fluorouracil Concentration During Continuous 5-Fluorouracil Infusion for Colorectal Cancer. H. MATSUMOTO, H. OKUMURA, H. MURAKAMI, H. KUBOTA, M. HIGASHIDA, A. TSURUTA, K. TOHYAMA, T. HIRAI (<i>Kurashiki City, Okayama, Japan</i>)	6193
Visualization of the Stomach's Arterial Networks During Esophageal Surgery Using the HyperEye Medical System. H. KITAGAWA, T. NAMIKAWA, M. MUNEKAGE, T. AKIMORI, M. KOBAYASHI, K. HANAZAKI (<i>Nankoku; Sukumo, Kochi, Japan</i>)	6201
Number of Lymph Node Metastases May Indicate the Regimen for Adjuvant Chemotherapy in Patients with Stage III Colorectal Cancer. K. ANDO, E. OKI, H. SAEKI, Y. KASAGI, Y. TSUDA, Y. ZAITSU, Y. NAKASHIMA, Y. IMAMURA, K. OHGAKI, Y. MAEHARA (<i>Fukuoka, Japan</i>)	6207
Adult Pleomorphic Rhabdomyosarcoma: A Multicentre Retrospective Study. J. NOUJAIM, K. THWAY, R.L. JONES, A. MIAH, K. KHABRA, R. LANGER, B. KASPER, I. JUDSON, C. BENSON, A. KOLLÄR (<i>London, UK; Bern, Switzerland; Mannheim, Germany</i>)	6213
A Tool to Estimate Survival of Elderly Patients Presenting with Metastatic Epidural Spinal Cord Compression (MESCC) from Cancer of Unknown Primary. D. RADES, A.J. CONDE-MORENO, R. GARCIA, T. VENINGA, S.E. SCHILD (<i>Lübeck, Germany; Castellón, Spain; Tilburg, the Netherlands; Scottsdale, AZ, USA</i>)	6219
Methylation-associated Silencing of microRNA-126 and its Host Gene <i>EGFL7</i> in Malignant Pleural Mesothelioma. M. ANDERSEN, D. TRAPANI, J. RAVN, J.B. SØRENSEN, C. BØGELUND ANDERSEN, M. GRAUSLUND, E. SANTONI-RUGIU (<i>Copenhagen, Denmark</i>)	6223
Postoperative External Irradiation of Patients with Primary Biliary Tract Cancer: A Multicenter Retrospective Study. K. HAYASHI, F. ISOHASHI, K. OGAWA, H. OIKAWA, H. ONISHI, Y. ITO, M. TAKEMOTO, K. KARASAWA, M. IMAI, Y. KOSAKA, H. YAMAZAKI, Y. YOSHIOKA, K. NEMOTO, Y. NISHIMURA and THE JAPANESE RADIATION ONCOLOGY STUDY GROUP (JROSG) (<i>Osaka; Iwate; Yamanashi; Tokyo; Okayama; Shizuoka; Hyogo; Kyoto; Yamagata, Japan</i>)	6231
Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach. L. AGOLLI, M. VALERIANI, L. NICOSIA, S. BRACCI, V. DE SANCTIS, G. MINNITI, R.M. ENRICI, M.F. OSTI (<i>Rome, Italy</i>)	6239

Active Hexose-correlated Compound Down-regulates Heat Shock Factor 1, a Transcription Factor for HSP27, in Gemcitabine-resistant Human Pancreatic Cancer Cells. M. TOKUNAGA, B. BARON, T. KITAGAWA, K. TOKUDA, Y. KURAMITSU (<i>Ube, Yamaguchi, Japan</i>)	6063
Cell Membrane Perforation with Photosensitizer and a Brush-shaped Soft-polymer Sheet Using a Malignant Glioma Cell Line. T. TACHIBANA, Y. SUZUKI, K. FUJIOKA, K. IKEDA, Y. INOUE, Y. TADA, T.K. SAITO, Y. MANOME (<i>Tokyo; Iwate; Yurihonjo City, Akita, Japan</i>)	6069
Bis(phenylidenebenzeneamine)-1-disulfide Derivatives Induce Autophagy in Melanoma Cells Through a Mitochondria-mediated Pathway. W.-P. HU, C.-C. HSU, Y.-C. WANG, G.C. SENADI, K.-K. KUO, J.-F. JEN, J.-J. WANG (<i>Kaohsiung; Taichung, Taiwan, ROC</i>)	6075
<i>Clinical Studies</i>	
Negative and Positive Consequences of Cancer Treatment Experienced by Long-term Osteosarcoma Survivors: A Qualitative Study. L. FAUSKE, H. BONDEVIK, Ø.S. BRULAND, G. OZAKINCI (<i>Oslo, Norway; Fife, Scotland, UK</i>)	6081
Dosimetric and Radiobiological Evaluation of Hybrid Inverse Planning and Optimization for Cervical Cancer Brachytherapy. L.D.S. MATIAS, T. PALMQVIST, J. WOLKE, J. NILSSON, C. BESKOW, A.M. MAPHOSSA, I. TOMA-DASU (<i>Stockholm, Sweden; Maputo, Mozambique</i>)	6091
Incisional Recurrences After Endometrial Cancer Surgery. G. BOGANI, S.C. DOWDY, W.A. CLIBY, B.S. GOSTOUT, S. KUMAR, F. GHEZZI, F. MULTINU, A. MARIANI (<i>Rochester, MN, USA; Varese, Italy</i>)	6097
Laparoendoscopic Single-site Surgery (LESS) for Prophylactic Salpingo-oophorectomy Improves Cosmetic Satisfaction Compared to Standard Laparoscopy. G. MIALHE, S. DAUCHY, E. BENTIVEGNA, S. GOUY, C. CHARLES, S. DELALOGUE, P. MORICE, C. UZAN (<i>Villejuif; Boulogne, France</i>)	6105
Tumor Budding, EMT and Cancer Stem Cells in T1-2/N0 Oral Squamous Cell Carcinomas. C.G. ATTRAMADAL, S. KUMAR, M.E. BOYSEN, H.P. DHAKAL, J.M. NESLAND, M. BRYNE (<i>Oslo, Norway</i>)	6111
Electrochemotherapy of a Multirecurrent Dermatofibrosarcoma Protuberans of the Orbital Margin: A Case Report. A. BONADIES, F. ELIA, F.M. SOLIVETTI, A. VIDIRI, L. MUSCARDIN, S. BUCHER (<i>Rome, Italy</i>)	6121
Endoplasmic Reticulum Stress in Pancreatic Neuroendocrine Tumors is Linked to Clinicopathological Parameters and Possible Epigenetic Regulations. E. KLIESER, R. ILLIG, S. STÄTTNER, F. PRIMAVESI, T. JÄGER, S. SWIERCZYNSKI, T. KIESSLICH, R. KEMMERLING, C. BOLLMANN, P. DI FAZIO, D. NEUREITER (<i>Salzburg, Austria; Trier; Marburg, Germany</i>)	6127
Low Serum Testosterone But Not Obesity Predicts High Gleason Score at Biopsy Diagnosed as Prostate Cancer in Patients with Serum PSA Lower than 20 ng/ml. M. SHIOTA, A. TAKEUCHI, M. SUGIMOTO, T. DEJIMA, E. KASHIWAGI, K. KIYOSHIMA, J. INOKUCHI, K. TATSUGAMI, A. YOKOMIZO (<i>Fukuoka, Japan</i>)	6137
Long-term Follow-up After Interstitial Laser Thermotherapy of Breast Cancer. K.-H. HARALDSDÓTTIR, C. INGVAR, U. STENRAM, K.-G. TRANBERG (<i>Lund, Sweden</i>)	6147
Gene Expression of <i>Col11A1</i> Is a Marker Not Only for Pancreas Carcinoma But Also for Adenocarcinoma of the Papilla of Vater, Discriminating Between Carcinoma and Chronic Pancreatitis. R. KLEINERT, K. PRENZEL, N. STOECKLEIN, H. ALAKUS, E. BOLLSCHWEILER, A. HÖLSCHER, U. WARNECKE-EBERZ (<i>Cologne; Düsseldorf, Germany</i>)	6153
Four Synchronous Primary Malignancies of the Breast, Lung, Colon and Esophagus. M. KLAIMONT, K. KOPKASH, J. FAVUZZA, M. HILL, R. RAO, B. MAHON, C.W. SEDER (<i>Chicago, IL, USA</i>)	6159

Fluorinated β -Diketo Phosphorus Ylides Are Novel Inhibitors of the ABCB1 Efflux Pump of Cancer Cells. G. SPENGLER, I. OCSOVSZKI, Á. SZABÓ TÖNKI, R. SAIJO, G. WATANABE, M. KAWASE, J. MOLNÁR (<i>Szeged, Hungary; Ehime, Japan</i>)	5915
<i>In Vitro</i> Efficacy of Naftifine Against Lymphoma and Multiple Myeloma. L.C. SCHMEEL, F.C. SCHMEEL, S. BLAUM-FEDER, I.G.H. SCHMIDT-WOLF (<i>Bonn, Germany</i>)	5921
Intercellular HOCl-mediated Apoptosis Induction in Malignant Cells: Interplay Between NOX1-Dependent Superoxide Anion Generation and DUOX-related HOCl-generating Peroxidase Activity. S.J. POTTGIESSER, S. HEINZELMANN, G. BAUER (<i>Freiburg, Germany</i>)	5927
Evaluation of ^{111}In -labeled Anginex as Potential SPECT Tracer for Imaging of Tumor Angiogenesis. T.R. VAN MOURIK, T. LÄPPCHEN, R. ROSSIN, J.R. VAN BEIJNUM, J.R. MACDONALD, K.H. MAYO, A.W. GRIFFIOEN, K. NICOLAY, H. GRÜLL (<i>Eindhoven; Amsterdam, the Netherlands; Excelsior; Minneapolis, MN, USA</i>)	5945
Site-specific Effects of DUOX1-Related Peroxidase on Intercellular Apoptosis Signaling. S. HEINZELMANN, G. BAUER (<i>Freiburg, Germany</i>)	5955
Crizotinib Fails to Enhance the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Xenografts. A.M. BASCHNAGEL, S. GALOFORO, B.J. THIBODEAU, S. AHMED, S. NIRMAL, J. AKERVALL, G.D. WILSON (<i>Madison, WI; Royal Oak, MI, USA</i>)	5973
Synergistic Effect of SN-38 in Combination with Cetuximab on Angiogenesis and Cancer Cell Invasion. M.H. PHAM, L. DELESTRE, A. DEWITTE, N. WATTEZ, F. LEPRETRE, A. LANSIAUX (<i>Lille; Paris, France</i>)	5983
Identification of the Critical Site of Calponin 1 for Suppression of Ovarian Cancer Properties. T. YAMANE, K. ASANOMA, H. KOBAYASHI, G. LIU, H. YAGI, T. OHGAMI, A. ICHINOE, K. SONODA, N. WAKE, K. KATO (<i>Fukuoka; Kagoshima, Japan</i>)	5993
Antitumor Activity of 3-Indolylmethanamines 31B and PS121912. M.L. GUTHRIE, P.S. SIDHU, E.K. HILL, T.C. HORAN, P. NANDHIKONDA, K.A. TESKE, N.Y. YUAN, M. SIDORKO, R. RODALI, J.M. COOK, L. HAN, N.R. SILVAGGI, D.D. BIKLE, R.G. MOORE, R.K. SINGH, L.A. ARNOLD (<i>Providence, RI; Milwaukee, WI; San Francisco, CA, USA</i>)	6001
Plasminogen Activation System in Rectal Adenocarcinoma. E. RAZIK, C. KOBIERZYCKI, J. GRZEGRZOLKA, M. PODHORSKA-OKOLOW, M. DRAG-ZALESINSKA, M. ZABEL, P. DZIEGIEL (<i>Wroclaw; Poznan, Poland</i>)	6009
Expression of MCM-3 and MCM-7 in Primary Cutaneous T-cell Lymphomas. A. JANKOWSKA-KONSUR, C. KOBIERZYCKI, A. REICH, J. GRZEGRZOLKA, J. MAJ, P. DZIEGIEL (<i>Wroclaw, Poland</i>)	6017
Combination of Genistein and Cisplatin with Two Designed Monofunctional Platinum Agents in Human Ovarian Tumour Models. L. ARZUMAN, P. BEALE, N. PROSCHOGO, J.Q. YU, F. HUQ (<i>Lidcombe; Concord; Sydney, NSW, Australia</i>)	6027
Effects of Vitamin K ₃ and K ₅ on Daunorubicin-resistant Human T Lymphoblastoid Leukemia Cells. E. NAKAOKA, S. TANAKA, K. ONDA, K. SUGIYAMA, T. HIRANO (<i>Hachioji, Japan</i>)	6041
Increased Expression of MuRF1 Is Associated with Radiation-induced Laryngeal Muscle Atrophy. X. HAN, L. PIRES, J.D. BROWNE, C.A. SULLIVAN, W. ZHAO, X. FENG (<i>Winston-Salem, NC, USA; Tangshan, HeBei, PR China</i>)	6049
Investigation of Interleukin-1 β Polymorphisms in Prostate Cancer. F. YENCILEK, A. YILDIRIM, S.G. YILMAZ, E.M. ALTINKILIC, A.B. DALAN, Y. BASTUG, T. ISBIR (<i>Istanbul, Turkey</i>)	6057

Brain Metastases in NSCLC – Are TKIs Changing the Treatment Strategy? W.C.M. DEMPKE, K. EDVARDBSEN, S. LU, N. REINMUTH, M. RECK, A. INOUE (<i>Cambridge, UK; Munich; Grosshansdorf, Germany; Shanghai, PR China; Sendai, Japan</i>)	5797
Primary Breast Cancer with Synchronous Metastatic Disease – Indications for Local Radiotherapy to the Breast and Chest Wall. S. JANSSEN, D. RADES (<i>Hannover; Lübeck, Germany</i>)	5807
<i>Experimental Studies</i>	
Electrochemotherapy – Evidence for Cell-type Selectivity <i>In Vitro</i> . F. LANDSTRÖM, M. IVARSSON, A. KOSKELA VON SYDOW, A. MAGNUSON, M. VON BECKERATH, C. MÖLLER (<i>Örebro, Sweden</i>)....	5813
Recruitment of Cancer-Associated Fibroblasts and Blood Vessels by Orthotopic Liver Tumors Imaged in Red Fluorescent Protein (RFP) Transgenic Nude Mice. A. SUETSUGU, Y. HIROSHIMA, T. MATSUMOTO, K. HASAGAWA, M. NAKAMURA, M. SHIMIZU, S. SAJI, H. MORIWAKI, M. BOUVET, R.M. HOFFMAN (<i>Gifu, Japan; San Diego, CA, USA</i>)	5821
Inhibiting Heat Shock Proteins Can Potentiate the Cytotoxic Effect of Cannabidiol in Human Glioma Cells. K.A. SCOTT, J.L. DENNIS, A.G. DALGLEISH, W.M. LIU (<i>London, UK</i>)	5827
Up-regulation of Toll-like Receptor 9 in Osteosarcoma. Y. JING, H. LIANG, Y. ZHANG, J. CLEVELAND, J. YAN, D. ZHANG (<i>Harbin, PR China; Houston, TX, USA</i>).....	5839
Breast Cancer Cell Lines Exhibit Differential Sensitivities to Microtubule-targeting Drugs Independent of Doubling Time. A.L. RISINGER, N.F. DYBDAL-HARGREAVES, S.L. MOOBERRY (<i>San Antonio, TX, USA</i>).....	5845
A Theoretical Model for the Hormetic Dose-response Curve for Anticancer Agents. T. YOSHIMASU, T. OHASHI, S. OURA, Y. KOKAWA, M. KAWAGO, Y. HIRAI, M. MIYASAKA, H. NISHIGUCHI, S. KAWASHIMA, Y. YATA, M. HONDA, T. FUJIMOTO, Y. OKAMURA (<i>Wakayama, Japan</i>)	5851
Microcystin LR Shows Cytotoxic Activity Against Pancreatic Cancer Cells Expressing the Membrane OATP1B1 and OATP1B3 Transporters. V. KOUNNIS, G. CHONDROGIANNIS, M.D. MANTZARIS, A.G. TZAKOS, D. FOKAS, N.A. PAPANIKOLAOU, V. GALANI, I. SAINIS, E. BRIASOULIS (<i>Oxford, UK; Ioannina; Thessaloniki, Greece</i>).....	5857
Expression of Estrogen Receptors in OSCC in Relation to Histopathological Grade. C. DOLL, R. ARSENIC, H. LAGE, K. JÖHRENS, S. HARTWIG, K. NELSON, J.D. RAGUSE (<i>Berlin; Freiburg, Germany</i>)	5867
The FGFR Inhibitor NVP-BGJ398 Induces NSCLC Cell Death by Activating Caspase-dependent Pathways as well as Caspase-independent Apoptosis. A. GÖKE, R. GÖKE, A. OFNER, A. HERBST, B. LANKAT-BUTTGEREIT (<i>Marburg; Munich, Germany</i>).....	5873
Oxidative Stress Activates Membrane Ion Channels in Human Biliary Epithelial Cancer Cells (Mz-Cha-1). T. SCHLENKER, L. SCHWAKE, A. VOSS, W. STREMMEL, C. ELSING (<i>Heidelberg; Dorsten, Germany</i>)	5881
Inhibition of Growth of Bladder Cancer Cells by 3-(3-Pyridinyl)-1-(4-pyridinyl)-2-propen-1-one in Combination with Other Compounds Affecting Glucose Metabolism. M.A. LEA, M. ALTAYYAR, C. DESBORDES (<i>Newark; Brooklyn, NY, USA</i>)	5889
HER2 Codon 655 (Ile/Val) Polymorphism and Breast Cancer in Austrian Women. R. WATROWSKI, D. CACSIRE CASTILLO-TONG, A. WOLF, E. SCHUSTER, M.B. FISCHER, P. SPEISER, R. ZEILLINGER (<i>Freiburg, Germany; Vienna, Austria</i>)	5901
Core Needle Biopsy Wash Optimization: Enabling Specimen Integrity for both Cytological and Histological Evaluation. W.D. MOJICA, N.K. FRISCH, J.K. PATERSON (<i>Buffalo, NY, USA</i>)	5905